Prescription patterns and costs of acne/rosacea medications in Medicare patients vary by prescriber specialty
- PMID: 28651825
- PMCID: PMC5557700
- DOI: 10.1016/j.jaad.2017.04.1127
Prescription patterns and costs of acne/rosacea medications in Medicare patients vary by prescriber specialty
Abstract
Background: Prescription patterns for acne/rosacea medications have not been described in the Medicare population, and comparisons across specialties are lacking.
Objective: To describe the medications used for treating acne/rosacea in the Medicare population and evaluate differences in costs between specialties.
Methods: A cross-sectional study was performed of the 2008 and 2010 Centers for Medicare and Medicaid Services Prescription Drug Profiles, which contains 100% of Medicare part D claims.
Results: Topical antibiotics accounted for 63% of all prescriptions. Patients ≥65 years utilized more oral tetracycline-class antibiotics and less topical retinoids. Specialists prescribed brand name drugs for the most common topical retinoids and most common topical antibiotics more frequently than family medicine/internal medicine (FM/IM) physicians by 6%-7%. Topical retinoids prescribed by specialists were, on average, $18-$20 more in total cost and $2-$3 more in patient cost than the same types of prescriptions from FM/IM physicians per 30-day supply. Specialists (60%) and IM physicians (56%) prescribed over twice the rate of branded doxycycline than FM doctors did (27%). The total and patient costs for tetracycline-class antibiotics were higher from specialists ($18 and $4 more, respectively) and IM physicians ($3 and $1 more, respectively) than they were from FM physicians.
Limitations: The data might contain rare prescriptions used for conditions other than acne/rosacea, and suppression algorithms might underestimate the number of specialist brand name prescriptions.
Conclusion: Costs of prescriptions for acne/rosacea from specialists are higher than those from primary care physicians and could be reduced by choosing generic and less expensive options.
Keywords: Medicare; acne; antibiotics; cost of care; prescription drug costs; rosacea; topical retinoids.
Copyright © 2017 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of Interest Disclosure: Dr. Kaffenberger serves on the advisory board of Castle Biosciences and has received research funds from Eli Lilly, XBiotech, Celgene, and Biogen.
Figures
References
-
- Davis SA, Feldman SR. Patterns of ambulatory care usage and leading treatments for rosacea. J Dermatolog Treat. 2014 Aug;25(4):275–277. - PubMed
-
- Romanowicz M, Stephenson JJ, Del Rosso JQ, Lenhart G. Healthcare utilization and costs of patients with rosacea in an insured population. J Drugs Dermatol. 2008 Jan;7(1):41–49. - PubMed
-
- Pena S, Hill D, Feldman SR. Use of topical retinoids by dermatologists and non-dermatologists in the management of acne vulgaris. J Am Acad Dermatol. 2016 Jun;74(6):1252–1254. - PubMed
-
- Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol. 2006 Sep;55(3):490–500. - PubMed
-
- Barbieri JS, Hoffstad O, Margolis DJ. Duration of oral tetracycline-class antibiotic therapy and use of topical retinoids for the treatment of acne among general practitioners (GP): A retrospective cohort study. J Am Acad Dermatol. 2016 Dec;75(6):1142–1150. e1141. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
